Biotechnology

A landmark $1.2M order for its advanced LineaDNA validates the firm's biotech arm, but can scientific success balance its new, volatile crypto strategy?

A new 10,000-sample 'skin library' collected by painless stickers aims to slash drug development time and costs for biopharmaceutical partners.

Gyre Therapeutics secures a pivotal conditional approval pathway in China for its novel liver fibrosis drug, offering hope for millions of hepatitis B patients.

A new partnership aims to unlock the potential of a next-gen obesity drug by pairing it with advanced delivery tech to overcome historical hurdles.

A new drug could redefine life for polycythemia vera patients, replacing frequent, burdensome blood draws with a simple weekly self-injection.

With a key drug decision looming and a refocused strategy, Rocket Pharmaceuticals faces a critical audience at the J.P. Morgan Healthcare Conference.

Tango Therapeutics adds seasoned CFO Sung Lee to its board, a strategic move to guide its lead cancer drug, vopimetostat, through late-stage trials.

Sanofi is investing up to $2.56 billion in Earendil Labs' AI platform to discover next-gen bispecific antibodies for complex autoimmune diseases.

With key trials in brain and prostate cancer, Curasight heads to a top investor conference to showcase its dual-action theranostic technology.

Abingworth elevates Bali Muralidhar and hires Travis Wilson, signaling a major push into clinical co-development and buyouts under Carlyle's wing.

All eyes are on GH Research ahead of a crucial Jan. 5 announcement on the FDA status of its fast-acting drug for treatment-resistant depression.

CDT Equity partners with a top advisory firm to license its drug-enhancing tech, tackling the patent cliff while managing a novel Bitcoin treasury strategy.

With a blockbuster 2025 in the books, Boston Scientific's leadership faces intense scrutiny at upcoming investor events to prove its growth is sustainable.

Genelux appoints Dr. Jason Litten as CMO, a strategic move to steer its promising oncolytic virus, Olvi-Vec, through crucial late-stage cancer trials.

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

BridgeBio Pharma hosts a key investor webinar on its oral drug infigratinib for achondroplasia, setting the stage for crucial trial results in Q1 2026.

Fresh off a major drug approval, Insmed's upcoming J.P. Morgan talk is under scrutiny as investors eye pipeline updates and acquisition potential.

Ironwood Pharma forecasts a massive profit jump by lowering its top drug's price, a bold move as it advances its rare disease pipeline for future growth.

With patent cliffs looming and big bets on M&A, all eyes are on BMS to prove its growth strategy and high-stakes pipeline can deliver in 2026.

The strategic separation of MarathonLS into two specialized firms aims to boost growth and service in the competitive life sciences support sector.